Decreasing systemic toxicity via transdermal delivery of anticancer drugs

被引:21
作者
Fang, Jia-You [2 ]
Liu, Pei-Feng [1 ,3 ]
Huang, Chun-Ming [1 ,3 ,4 ]
机构
[1] Univ Calif San Diego, Dept Med, Div Dermatol, San Diego, CA 92161 USA
[2] Chang Gung Univ, Grad Inst Nat Prod, Pharmaceut Lab, Tao Yuan, Taiwan
[3] VA San Diego Healthcare Ctr, San Diego, CA USA
[4] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA
基金
美国国家卫生研究院;
关键词
toxicity; transdermal delivery; laser; anticancer drugs;
D O I
10.2174/138920008785821693
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
When used at a high dose, many anticancer drugs produce undesirable side effects including hepatotoxicity. Transdermal delivery bypasses first-pass metabolism, allowing the use of a lower dose of drug while decreasing systemic toxicity. In this review, we summarize various advanced technologies for improving anticancer drug delivery via the skin. This technology is discussed in the context of three anticancer drugs, 5-fluorouracil (5-FU), methotrexate (MTX) and 5-aminolevulinic acid (5-ALA). The use of a erbium: YAG ( Er: YAG) laser for transdermal delivery of anticancer drugs is specifically highlighted in this review.
引用
收藏
页码:592 / 597
页数:6
相关论文
共 87 条
[1]   White-light toxicity, resulting from systemically administered 5-aminolevulinic acid, under normal operating conditions [J].
Aalders, MCG ;
Van der Vange, N ;
Stewart, FA ;
Klein, MG ;
Van der Vijver, MJ ;
Sterenborg, HJCM .
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, 1999, 50 (2-3) :88-93
[2]   Influence of lipophilic counter-ions in combination with phloretin and 6-ketocholestanol on the skin permeation of 5-aminolevulinic acid [J].
Auner, BG ;
Valenta, C ;
Hadgraft, J .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 255 (1-2) :109-116
[3]   Iontophoresis and electroporation: comparisons and contrasts [J].
Banga, AK ;
Bose, S ;
Ghosh, TK .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 179 (01) :1-19
[4]   Clinical pharmacokinetics of the PDT photosensitizers porfimer sodium (Photofrin), 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (Photochlor) and 5-ALA-induced protoporphyrin IX [J].
Bellnier, David A. ;
Greco, William R. ;
Loewen, Gregory M. ;
Nava, Hector ;
Oseroff, Allan R. ;
Dougherty, Thomas J. .
LASERS IN SURGERY AND MEDICINE, 2006, 38 (05) :439-444
[5]   Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics [J].
Berger, N ;
Sachse, A ;
Bender, J ;
Schubert, R ;
Brandl, M .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 223 (1-2) :55-68
[6]   Hepatotoxicity and metabolism of trabectedin: a literature review [J].
Beumer, JH ;
Schellens, JHM ;
Beijnen, JH .
PHARMACOLOGICAL RESEARCH, 2005, 51 (05) :391-398
[7]   Neoadjuvant chemotherapy for metastatic colon cancer: A cautionary note [J].
Bilchik, AJ ;
Poston, G ;
Curley, SA ;
Strasberg, S ;
Saltz, L ;
Adam, R ;
Nordlinger, B ;
Rougier, P ;
Rosen, LS .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9073-9078
[8]   Skin structure and mode of action of vesicles [J].
Bouwstra, JA ;
Honeywell-Nguyen, PL .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 :S41-S55
[9]   Clinical pharmacokinetics of 2′-deoxy-2′-methylidenecytidine (DMDC), a deoxycytidine analogue antineoplastic agent [J].
Brindley, CJ ;
Morrison, R ;
Gordon, RJ ;
Devlin, AJ ;
van der Gaast, A ;
Verweij, J ;
Funaki, T .
CLINICAL PHARMACOKINETICS, 2000, 38 (06) :475-491
[10]  
Brown Marc B., 2008, V437, P119, DOI 10.1007/978-1-59745-210-6_5